Refractory Chronic Migraine
Conditions
Brief summary
Ketamine and lidocaine infusion for refractory chronic migraine: Comparative Study
Interventions
group A will receive ketamine intravenous infusion
group B will receive lidocaine intravenous infusion
group C will only receive Dextrose 5% in water
Sponsors
Assiut University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Inclusion criteria
* All participants must fulfill the following inclusion criteria 1. medically stable outpatients with confirmed diagnosis of refractory chronic migraine according to American Headache society 2. Are reliable and willing to make themselves available for the duration of the study and are willing to follow up. 3. Men or women older than 18years of age. 4. clear written informed consent from each participant in the trial. 5. Adult patients with refractory migraine or refractory chronic migraine defined according to the American headache society
Exclusion criteria
1. Pregnancy, active psychosis, liver disease, uncontrolled cardiac disease or cardiac rhythm abnormalities 2. presence of clinically significant medical or psychiatric condition that may increase the risk associated with the study 3. participation in any other type of medical research that may interfere with the interpretation of the study. 4. patients with hemocoagulation disorders, local infection or those who refused to consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in pain scale using Numeric rating scale | From enrollment to the end of treatment at 6 weeks | Pain assessment by using a Numeric rating scale (0 (no pain) to 10 (worst possible pain). Scores of 1-3 are considered mild, 4-6 moderate, and 7-10 severe) before the infusion and daily for 1-week post infusion, then weekly for 6 weeks post infusion |
| Changes in pain scale using Migraine disability assessment | From enrollment to the end of treatment at 6 weeks | Migraine disability assessment test before the infusion and daily for 1-week post infusion, then weekly for 6 weeks post infusion |
Contacts
Primary ContactAbdElRahman Mohamed Mohamed
Outcome results
None listed